Literature DB >> 11079621

Clinicopathologic characteristics of early gastric cancer in Korea.

I S Park1, Y C Lee, W H Kim, S H Noh, K S Lee, H Kim.   

Abstract

Gastric cancer is the most common cause of cancer related death in Korea. Early gastric cancer (EGC), confined to mucosa or submucosa, regardless of lymph node metastasis, is known to have a favorable prognosis. From 1976 to 1995, four thousand nine hundred and twenty eight gastric cancer patients underwent operation at the Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea. Of these, 1,117 patients (22.6%) were diagnosed as EGC and underwent curative operation. Clinicopathologic characteristics were reviewed and survival data was analyzed. The proportion of EGC has increased during the last two decades, from 14.9% during 1976-1985 to 25.8% for 1986-1995. EGC has a wide age distribution range from the thirties to the sixties, with highest incidence in the sixties. The male to female ratio is 1.8:1, without any significant change in last two decades. Most lesions are located in the lower third of stomach (52.3%), and the lesser curvature (52.2%) was the most frequent site in the transverse axis. Macroscopically, the depressed type was the most common (66.1%) followed by the elevated, flat and mixed types, in that order. Tumor confined to the mucosa layer was seen in 52.5%, and lymph node involvement in 11.7%. The depth of tumor invasion correlated with tumor size and regional lymph node involvement. On histopathologic examination, signet ring cell type accounted for 29.6% of all EGCs. Overall 5-year survival rate was 92.7% and the presence of lymph node metastasis significantly affected survival (84.6% versus 96.2%) (p<0.05). In conclusion, the proportion of EGC, in terms of the gastric cancers operated upon, has been increasing in Korea over the last two decades. The introduction of active diagnostic approaches and diagnostic modalities could improve early diagnosis and the cure rate of gastric cancer in Korea.

Entities:  

Mesh:

Year:  2000        PMID: 11079621     DOI: 10.3349/ymj.2000.41.5.607

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  7 in total

1.  Worldwide experiences of endoscopic submucosal dissection: not just Eastern acrobatics.

Authors:  Kwang Bum Cho; Won Joong Jeon; Jae J Kim
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

2.  Long-term survival results and prognostic factors of early gastric cancer.

Authors:  Baojun Huang; Zhenning Wang; Chengzhong Xing; Zhe Sun; Bo Zhao; Huimian Xu
Journal:  Exp Ther Med       Date:  2011-07-26       Impact factor: 2.447

3.  Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway.

Authors:  Seung-Hyun Hong; Sung-Ho Goh; Sang Jin Lee; Jung-Ah Hwang; Jieun Lee; Il-Ju Choi; Hyehyun Seo; Jong-Hoon Park; Hiromu Suzuki; Eiichiro Yamamoto; In-Hoo Kim; Jin Sook Jeong; Mi Ha Ju; Dong-Hee Lee; Yeon-Su Lee
Journal:  Oncotarget       Date:  2013-10

4.  Prevalence of Precancerous Conditions and Gastric Cancer Based upon the National Cancer Screening Program in Korea for 7 Years, Single Center Experience.

Authors:  Ji Hyuk Kang; Yun Jeong Lim; Jung Hyun Kang; Jae Nam Yang; Seung Min Shin; Jae Hyeuk Choi; Jin Ho Lee
Journal:  Gastroenterol Res Pract       Date:  2015-01-06       Impact factor: 2.260

5.  Prognostic effect of different etiologies in patients with gastric cardia cancer.

Authors:  Yeon-Ji Kim; Woo Chul Chung; Ik Hyun Cho; Jaeyoung Kim; Seonhoo Kim
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

6.  Lymph Node Metastasis, a Unique Independent Prognostic Factor in Early Gastric Cancer.

Authors:  Bai-Wei Zhao; Yong-Ming Chen; Shan-Shan Jiang; Yin-Bo Chen; Zhi-Wei Zhou; Yuan-Fang Li
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

7.  Is adjuvant chemotherapy necessary in pT1N1 gastric cancer?

Authors:  Hyun Beak Shin; Ji Yeong An; Seung Hyoung Lee; Yoon Young Choi; Jong Won Kim; Soo Sang Sohn; Sung Hoon Noh
Journal:  BMC Cancer       Date:  2017-04-22       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.